EGFR and neoplasm: Regardless of the resistance mechanisms that eventually will develop, it is conceivable that the enhancement in cell death associated with osimertinib/chemotherapy combination, presumably triggered also in vivo, may postpone the emergence of resistance to EGFR-TKIs by limiting the original tumor heterogeneity.